Á lódáil...
Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
Ibrutinib (PCI-32765) is an irreversible dual Btk/Itk inhibitor shown to be effective in treating several B cell malignancies. However, limited studies have been conducted to study the effect of this drug on myeloid cell function. Hence, we studied the effect of ibrutinib treatment on TLR-4 mediated...
Na minha lista:
Foilsithe in: | Oncoimmunology |
---|---|
Main Authors: | , , , , , , |
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
Taylor & Francis
2015
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4760285/ https://ncbi.nlm.nih.gov/pubmed/26942065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1057385 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|